Company news

Gilead Sciences, Inc. (NASDAQ:GILD) news

Gilead Sciences, Inc. news releases on 6ix. Latest, Sep 17, 2026: Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

Gilead Sciences, Inc. (NASDAQ:GILD) news

Press releases & updates

Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

Gilead Sciences : Breaks Ground on New Biologics Facility as Part of $32 Billion U.S. R&D and Manufacturing Investment

U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences

European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

Gilead Sciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences : Statement on California Supreme Court Decision in TDF Litigation

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

Gilead Sciences : Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease

U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer

European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors

U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention

Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief

National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)

FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease

Gilead Prices $3 Billion of Senior Unsecured Notes

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

National casting call for E. Lynn Harris Invisible Life: The Musical With Original Score by Ashford & Simpson Announced

Gilead Sciences Announces First Quarter Financial Results

Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences

U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities

Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

Gilead Sciences : Publishes 2025 Responsible Business and Impact Report, Highlighting Momentum Toward 2030 Ambitions

Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer

PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access

Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE

Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Gilead Extends Tender Offer to Acquire Arcellx

Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy